GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (STU:ER4) » Definitions » Cyclically Adjusted PS Ratio

Emergent BioSolutions (STU:ER4) Cyclically Adjusted PS Ratio : 0.23 (As of May. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Emergent BioSolutions Cyclically Adjusted PS Ratio?

As of today (2024-05-26), Emergent BioSolutions's current share price is €4.313. Emergent BioSolutions's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €18.44. Emergent BioSolutions's Cyclically Adjusted PS Ratio for today is 0.23.

The historical rank and industry rank for Emergent BioSolutions's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:ER4' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.08   Med: 4.2   Max: 12.78
Current: 0.24

During the past years, Emergent BioSolutions's highest Cyclically Adjusted PS Ratio was 12.78. The lowest was 0.08. And the median was 4.20.

STU:ER4's Cyclically Adjusted PS Ratio is ranked better than
92.33% of 743 companies
in the Drug Manufacturers industry
Industry Median: 2.11 vs STU:ER4: 0.24

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Emergent BioSolutions's adjusted revenue per share data for the three months ended in Mar. 2024 was €5.153. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €18.44 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Emergent BioSolutions Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Emergent BioSolutions's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions Cyclically Adjusted PS Ratio Chart

Emergent BioSolutions Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.51 7.64 2.90 0.68 0.13

Emergent BioSolutions Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.58 0.40 0.18 0.13 0.13

Competitive Comparison of Emergent BioSolutions's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emergent BioSolutions's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's Cyclically Adjusted PS Ratio falls into.



Emergent BioSolutions Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Emergent BioSolutions's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=4.313/18.44
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emergent BioSolutions's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Emergent BioSolutions's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=5.153/131.7762*131.7762
=5.153

Current CPI (Mar. 2024) = 131.7762.

Emergent BioSolutions Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 1.679 100.560 2.200
201409 1.565 100.428 2.054
201412 1.999 99.070 2.659
201503 0.743 99.621 0.983
201506 1.708 100.684 2.235
201509 2.403 100.392 3.154
201512 2.573 99.792 3.398
201603 1.325 100.470 1.738
201606 1.295 101.688 1.678
201609 2.008 101.861 2.598
201612 1.947 101.863 2.519
201703 1.873 102.862 2.399
201706 1.418 103.349 1.808
201709 2.215 104.136 2.803
201712 2.950 104.011 3.737
201803 1.666 105.290 2.085
201806 3.406 106.317 4.222
201809 2.586 106.507 3.200
201812 4.130 105.998 5.134
201903 2.919 107.251 3.587
201906 3.475 108.070 4.237
201909 4.795 108.329 5.833
201912 5.742 108.420 6.979
202003 2.957 108.902 3.578
202006 6.160 108.767 7.463
202009 5.618 109.815 6.742
202012 8.490 109.897 10.180
202103 4.958 111.754 5.846
202106 5.719 114.631 6.574
202109 4.940 115.734 5.625
202112 10.479 117.630 11.739
202203 5.335 121.301 5.796
202206 4.454 125.017 4.695
202209 4.504 125.227 4.740
202212 6.125 125.222 6.446
202303 2.936 127.348 3.038
202306 6.031 128.729 6.174
202309 4.775 129.860 4.845
202312 4.750 129.419 4.837
202403 5.153 131.776 5.153

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Emergent BioSolutions  (STU:ER4) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Emergent BioSolutions Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Emergent BioSolutions (STU:ER4) Business Description

Traded in Other Exchanges
Address
400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.

Emergent BioSolutions (STU:ER4) Headlines

No Headlines